ACAD — Acadia Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $2.46bn
- $1.70bn
- $957.80m
- 73
- 54
- 60
- 66
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 20.29 | ||
| PEG Ratio (f) | 1.12 | ||
| EPS Growth (f) | 22.19% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.35 | ||
| Price to Tang. Book | 4.01 | ||
| Price to Free Cashflow | 15.63 | ||
| Price to Sales | 2.57 | ||
| EV to EBITDA | 6.89 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 29.11% | ||
| Return on Equity | 38.89% | ||
| Operating Margin | 24.1% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 441.75 | 484.14 | 517.24 | 726.44 | 957.8 | 1,061.76 | 1,168.76 | 23.08% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | +2.99 | +62.21 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
Directors
- Stephen Biggar NEC (50)
- Srdjan Stankovic PRE (64)
- Stephen Davis CEO (60)
- Mark Schneyer CFO (47)
- Brendan Teehan COO (53)
- Austin Kim EVP (57)
- Charmaine Lykins SVP
- Amanda Morgan SVP
- Elizabeth Garofalo DRC (64)
- Julian Baker IND (54)
- Laura Brege IND (63)
- James Daly IND (59)
- Edmund Harrigan IND (68)
- Daniel Soland IND (63)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 16th, 1997
- Public Since
- May 27th, 2004
- No. of Shareholders
- 32
- No. of Employees
- 653
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 166,788,517
- Address
- 12830 El Camino Real, Suite 400, SAN DIEGO, 92130
- Web
- https://acadia.com/
- Phone
- +1 8585582871
- Auditors
- Ernst & Young LLP
Upcoming Events for ACAD
Q1 2025 ACADIA Pharmaceuticals Inc Earnings Call
ACADIA Pharmaceuticals Inc Annual Shareholders Meeting
ACADIA Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 ACADIA Pharmaceuticals Inc Earnings Release
Similar to ACAD
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Acadia Pharmaceuticals share price?
As of Today at 19:02 UTC, shares in Acadia Pharmaceuticals are trading at $14.73. This share price information is delayed by 15 minutes.
How has the Acadia Pharmaceuticals share price performed this year?
Shares in Acadia Pharmaceuticals last closed at $14.73 and the price had moved by -9.69% over the past 365 days. In terms of relative price strength the Acadia Pharmaceuticals share price has underperformed the S&P500 Index by -16.64% over the past year.
What are the analyst and broker recommendations for Acadia Pharmaceuticals?
The overall consensus recommendation for Acadia Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Acadia Pharmaceuticals dividend yield?
Acadia Pharmaceuticals does not currently pay a dividend.
Does Acadia Pharmaceuticals pay a dividend?
Acadia Pharmaceuticals does not currently pay a dividend.
When does Acadia Pharmaceuticals next pay dividends?
Acadia Pharmaceuticals does not currently pay a dividend.
How do I buy Acadia Pharmaceuticals shares?
To buy shares in Acadia Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Acadia Pharmaceuticals?
As of the previous close price of $14.73, shares in Acadia Pharmaceuticals had a market capitalisation of $2.46bn.
Where are Acadia Pharmaceuticals shares listed?
Here are the trading details for Acadia Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ACAD
What kind of share is Acadia Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Acadia Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Acadia Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Acadia Pharmaceuticals is $24.22. That is 64.43% above the last closing price of $14.73.
Analysts covering Acadia Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $0.61 for the next financial year.
Find out moreWhat is the trend in the Acadia Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acadia Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +8.27%.
As of the last closing price of $14.73, shares in Acadia Pharmaceuticals were trading -12.38% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Acadia Pharmaceuticals PE Ratio?
The Acadia Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 20.29. The shares last closed at $14.73.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Acadia Pharmaceuticals?
Acadia Pharmaceuticals' management team is headed by:
- Stephen Biggar - NEC
- Srdjan Stankovic - PRE
- Stephen Davis - CEO
- Mark Schneyer - CFO
- Brendan Teehan - COO
- Austin Kim - EVP
- Charmaine Lykins - SVP
- Amanda Morgan - SVP
- Elizabeth Garofalo - DRC
- Julian Baker - IND
- Laura Brege - IND
- James Daly - IND
- Edmund Harrigan - IND
- Daniel Soland - IND